Trilantic, a private equity firm, completed the investment in SOFIE Biosciences, a radiopharmacy and contract development and manufacturing organization, from Jubilant Pharma, a global integrated pharmaceutical company. Financial terms were not disclosed. “The recent staggering increase in the adoption of radiopharmaceuticals in medicine provides SOFIE, and our scientific community, numerous opportunities to provide value through companion diagnostic development, and manufacturing of diagnostic and therapeutic products, at scale. Such an opportunity comes once in a lifetime. Trilantic is the right partner to make our full vision come true,” Patrick Phelps, SOFIE Co-Founder, President and CEO.